News
VYNE
2.560
+6.67%
0.160
VYNE Therapeutics Sees Strong Shareholder Support for Growth
TipRanks · 1d ago
Weekly Report: what happened at VYNE last week (1202-1206)?
Weekly Report · 4d ago
Weekly Report: what happened at VYNE last week (1125-1129)?
Weekly Report · 12/02 11:17
Weekly Report: what happened at VYNE last week (1118-1122)?
Weekly Report · 11/25 11:09
Vyne Therapeutics Price Target Announced at $8.00/Share by BTIG
Dow Jones · 11/18 13:49
BTIG Initiates Coverage On VYNE Therapeutics with Buy Rating, Announces Price Target of $8
Benzinga · 11/18 13:39
VYNE THERAPEUTICS INC <VYNE.O>: BTIG INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $8
Reuters · 11/18 12:17
VYNE Therapeutics initiated with a Buy at BTIG on I&I potential
TipRanks · 11/18 11:15
VYNE Therapeutics initiated with a Buy at BTIG
TipRanks · 11/18 11:10
Weekly Report: what happened at VYNE last week (1111-1115)?
Weekly Report · 11/18 11:06
U.S. RESEARCH ROUNDUP- Airbnb, Post Holdings, Syndax Pharmaceuticals
Reuters · 11/18 07:15
Weekly Report: what happened at VYNE last week (1104-1108)?
Weekly Report · 11/11 11:18
Vyne Therapeutics Inc <VYNE.OQ> expected to post a loss of 25 cents a share - Earnings Preview
Reuters · 11/08 16:31
Vyne Therapeutics Price Target Maintained With a $5.75/Share by HC Wainwright & Co.
Dow Jones · 11/08 10:21
HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $5.75 Price Target
Benzinga · 11/08 10:11
VYNE Therapeutics Advances Clinical Pipeline in Q3 2024
TipRanks · 11/08 06:13
VYNE Therapeutics: Robust Pipeline and Financial Stability Underpin Buy Rating
TipRanks · 11/07 15:15
VYNE Therapeutics: Promising Clinical Progress and Financial Stability Support Buy Rating
TipRanks · 11/07 15:05
VYNE Therapeutics GAAP EPS of -$0.29, revenue of $0.1M
Seeking Alpha · 11/07 14:15
VYNE THERAPEUTICS: AS OF SEPT 30, 2024, CO HAD CASH, CASH EQUIVALENTS, RESTRICTED CASH & MARKETABLE SECURITIES OF $70.2 MLN
Reuters · 11/07 13:12
More
Webull provides a variety of real-time VYNE stock news. You can receive the latest news about Vyne Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VYNE
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.